GI Dynamics Goes Down Under To Fund First Endoscopic Treatment For Diabetes
This article was originally published in The Gray Sheet
The Massachusetts-based developer of the EndoBarrier device is leveraging its presence on the Australian stock exchange to finance its drug-like clinical development changes.
You may also be interested in...
FDA and the company could not come up with a plan to continue the ENDO study for GI's device targeting obese patients with diabetes in response to higher-than-anticipated rates of liver infection. The company suggests, however, that development of the device will continue.
Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.
New CEO for GI Dynamics. Allergan names Jim Hindman CFO. HeartFlow makes executive suite changes; Biogen Idec appoints new executive VP.